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Background: Chronic obstructive pulmonary disease (COPD) is an increasing public health
problem worldwide. Although epidemiologic data on COPD are important to raise awareness
of the burden of disease, there are no actual spirometry-based data on the prevalence of COPD
in the Netherlands.
Methods: Using the Burden of Obstructive Lung Disease (BOLD) protocol and study design, a po-
pulation-based sample of adults, aged 40 years, in the area of Maastricht, the Netherlands
was surveyed. Post-bronchodilator spirometry and questionnaires with information on smoking
history and reported respiratory disease were collected. COPD was defined as post-
bronchodilator FEV1/FVC ratio < 0,7 (GOLD) or < the lower limit of normal (LLN) (95th percen-
tile) of the population distribution for FEV1/FVC. Data were statistically weighted for the total
number of people in the Maastricht population.
Results: Overall prevalence of COPD was 24%, and was higher for men (28.5%) than for women
(195%). (unweighted pZ 0.002) The prevalence of GOLD stage 2 or higher COPD was 10%. The
prevalence of LLN-defined COPD was 19% and 10% for stage 2 or higher. Overall prevalence of
current smoking was 23%. The prevalence of COPD increased with age and amount of pack-
years, although 14% of never smokers fulfilled spirometric criteria for COPD. The prevalence
of doctor-diagnosed COPD was only 8.8%.
Conclusion: Almost one quarter of the Maastricht population aged 40 years had COPD.
Considering the ageing population and still an important smoking prevalence, this burden is
bound to increase and imposes great demands to public health care and society in the
Netherlands.
ª 2012 Elsevier Ltd. All rights reserved.velopment Centre, CIROþ, Centre of Expertise for Chronic Organ Failure, Hornerheide 1, 6085 NM
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872 L.E.G.W. Vanfleteren et al.Introduction subjects whom the site attempted to contact (22 wereTable 1 Characteristics of subjects included in the anal-
yses e results are for observed sample only and are not
population estimates.
No. 592 (100%)
Age
40e49 160 (27%)
50e59 182 (31%)
60e69 167 (28%)
70þ 83 (14%)
Gender
Male 300 (51%)
Female 292 (49%)
Smoking status
Current 136 (23%)
Ex 252 (43%)
Never 204 (34%)
Doctor diagnosed asthma 60/591 (10%)
Doctor diagnosed COPD,
chronic bronchitis or emphysema
48/591 (8%)Chronic obstructivepulmonarydisease (COPD) is a serious and
increasing public health problem throughout the world.
Although preventable, COPD cannot be cured and causes high
levels of disability. This imposes increasing demands on
regional health care systems and a growing economic burden
on society. Lost productivity due to COPD has a particularly
high impact on theeconomy, accounting for 50%of theoverall
COPD-related societal cost in the Netherlands.1,2
Although epidemiologic data on COPD are important to
raise awareness of the burden of this disease, country-
specific studies on the current and future impact of COPD in
the Netherlands are scarce. Available date are mostly
based on physician’s diagnosis of ‘COPD’, ‘chronic bron-
chitis’ or ‘lung emphysema’.3 Moreover, COPD tends to be
underdiagnosed and undertreated by healthcare profes-
sionals in the Netherlands.2
Therefore, the aim of the present study was to assess
the prevalence of COPD and its risk factors in the general
population aged 40 years and older in Maastricht, the
Netherlands. To achieve both maximum accuracy and
completeness of the survey as well as high-quality post-
bronchodilator spirometry, the Burden of Obstructive Lung
Disease (BOLD)protocol andstudydesignwere implemented.4
Methods
A population-based cross-sectional study of the prevalence
of COPD in the area of Maastricht, the Netherlands was
conducted from October 2007 till March 2009. The BOLD
protocol and definitions of smoking history were followed.4
Municipal administrators sampled adults aged 40 years at
random from the population. Following a recruitment
letter, subjects were contacted by phone and a clinic visit
was scheduled. All participants gave written informed
consent. The study was approved by medical ethical
committee of Maastricht University Medical Centre.
COPD was defined according to GOLD5 or according to
the lower limit of normal (LLN), which is beneath the 95th
percentile of population distribution for the FEV1/FVC ratio
according to NHANES.6 COPD stage 2 or higher was defined
as FEV1 <80% of predicted. Doctor-diagnosed COPD was
defined as a self-reported physician’s diagnosis of chronic
bronchitis, emphysema, or COPD.
Prevalence estimates for the overall Maastricht pop-
ulation, as well as for subgroups defined by gender and either
age or pack-years of cigarette smoking were calculated using
the Stata package (Stata Corporation, College Station, TX
USA). Weighting class adjustments were made to adjust for
differential response rates for the eight categories defined by
gender and age, to assure that theestimatedprevalences and
SEs properly reflect the sampling design. Differences within
the study samplewere calculatedon theunweighteddataset,
using two-sided p-value based on Pearson chi-square test.
Results
A total of 634 of 1345 subjects (47%) selected for recruit-
ment signed informed consent. This is 48% of the 1323ineligible), and 55% of the 1147 succesfully contacted
subjects. Compared to participants subjects who denied
participation or could not be reached were more prevalent
in the 70 þ age category (p < 0,05), but there were no
differences in gender (p > 0.05) or smoking history
(p > 0.05). Forty-two subjects were excluded because of
unacceptable post-bronchodilator spirometry. These were
more frequently current smokers compared to 592 subjects
included in the analyses (43% vs. 23%, p < 0,01). Baseline
characteristics are listed in Table 1.
Estimated population prevalence of GOLD- and LLN-
defined COPD by age, gender and smoking status is pre-
sented in Tables 2 and 3. The estimated prevalence of
doctor-diagnosed COPD was 8.8% (SE:1.2).
The estimated prevalence of current smoking was 23%
(SE:1.8) and was similar for both sexes (Male 24% (SE:2.4);
female 22% (SE:2.7)). The prevalence of ever smokers
(overall 63% (SE:2.1)) was higher in men (70% (SE:2.7)) than
in women 57% (SE:3.2)) (p < 0.001). The highest prevalence
of ever smokers was in men, 60e69 years old and was 85%
(SE:3.7). Thirty-one percent of the population ever smoked
more than 20 pack-years. Of these subjects, 22% had at
least GOLD stage 2 COPD and 11% had doctor diagnosed
COPD.
Discussion
Using BOLD4 methodology, this study showed that the
prevalence of GOLD-defined COPD in the general pop-
ulation aged 40 years and older in Maastricht, the
Netherlands is 24%. Ten percent of population had COPD
GOLD stage 2 or higher. Using the LLN to define COPD, still
19% had COPD and 10% had at least stage 2. The overall
prevalence of GOLD-defined COPD was higher in men than
in women. The estimated prevalence of current smokers
was 23%.
Based on five databases containing registrations of
physician’s diagnosis of COPD, chronic bronchitis or lung
Table 2 Estimated Population Prevalence of GOLD stage
1 or higher, GOLD stage 2 or higher, LLN stage 1 or higher,
LLN stage 2 or higher COPD by age and sex e Weighted
po-pulation estimate, with SE shown in parenthesis.
Age Male Female Total
GOLD 1 þ 40e49 9.0% (3.4) 5.8% (3.0) 7.4% (2.2)
50e59 27.4% (4.9) 18.4% (4.1) 22.9% (3.2)
60e69 37.0% (5.3) 18.4% (4.2)a 27.6% (3.5)
70þ 51.2% (7.7) 35.6% (8.2) 41.6% (5.9)
Total 28.5% (2.8) 19.5% (2.9)a 23.7% (2.0)
GOLD 2 þ 40e49 4.4% (2.6) 1.2% (1.2) 2.8% (1.4)
50e59 13.7% (3.8) 8.2% (3.1) 10.9% (2.4)
60e69 18.9% (4.4) 6.9% (2.7)a 12.8% (2.6)
70þ 19.9% (6.3) 15.6% (7.2) 17.3% (5.0)
Total 13.2% (2.1) 8.0% (2.3)a 10.4% (1.5)
LLN 1 þ 40e49 7.8% (3.2) 14.0% (4.1) 11.0% (2.6)
50e59 22.6% (4.6) 18.4% (4.1) 20.5% (3.1)
60e69 20.0% (4.5) 16.1% (4.0) 18.0% (3.0)
70þ 33.6% (7.4) 22.3% (7.7) 26.6% (5.5)
Total 19.7% (2.4) 17.8% (2.7) 18.7% (1.8)
LLN 2 þ 40e49 4.4% (2.6) 3.5% (2.0) 3.9% (1.6)
50e59 12.7% (3.7) 8.2% (3.1) 10.4% (2.4)
60e69 12.7% (3.7) 6.9% (2.7) 9.8% (2.3)
70þ 19.9% (6.3) 15.6% (7.2) 17.3% (5.0)
Total 11.6% (2.0) 8.6% (2.3) 10.0% (1.5)
a P < 0.05 on the unweighted population sample.
Table 3 Estimated Population Prevalence of GOLD stage 1
or higher, GOLD stage 2 or higher, LLN stage 1 or higher, LLN
stage 2 or higher COPD by pack years and sex e Weighted
population estimate, with SE shown in parenthesis.
Packyears Male Female Total
GOLD 1þ Never smokers 10.7% (3.5) 16.2% (4.1) 14.1% (2.8)
0e10 20.4% (5.6) 12.0% (5.3) 16.1% (3.8)
10e20 21.3% (6.3) 20.9% (7.0) 21.1% (4.7)
20þ 51.0% (5.0) 29.8% (6.7)a 41.2% (4.0)
Total 28.5% (2.8) 19.5% (2.9)a 23.7% (2.0)
GOLD 2þ Never smokers 4.8% (2.5) 2.0% (1.5) 3.1% (1.3)
0e10 8.3% (4.2) 4.6% (3.4) 6.4% (2.7)
10e20 4.0% (2.8) 7.0% (5.2) 5.5% (3.0)
20þ 26.4% (4.5) 20.6% (6.7) 23.7% (3.9)
Total 13.2% (2.1) 8.0% (2.3)a 10.4% (1.5)
LLN 1þ Never smokers 4.8% (2.5) 10.0% (3.1) 8.0% (2.2)
0e10 13.2% (4.8) 9.4% (4.7) 11.2% (3.4)
10e20 17.9% (5.9) 19.0% (6.9) 18.5% (4.5)
20þ 37.5% (4.9) 35.9% (6.7) 36.7% (4.1)
Total 19.7% (2.4) 17.8% (2.7) 18.7% (1.8)
LLN 2þ Never smokers 3.8% (2.3) 2.0% (1.5) 2.7% (1.3)
0e10 0.8% (4.2) 6.3% (3.7) 7.2% (2.8)
10e20 2.3% (2.3) 7.0% (5.2) 4.6% (2.9)
20þ 23.9% (4.4) 21.8% (6.7) 22.9% (3.9)
Total 11.6% (2.0) 8.6% (2.3) 10.0% (1.5)
a p < 0.05 on the unweighted population sample.
The prevalence of chronic obstructive pulmonary disease 873emphysema in primary care, the state institute for public
health and environment in the Netherlands (RIVM) esti-
mated the prevalence of COPD in 2007 as 1.8% for men and
1.6% for women.3 This reported prevalence does not
approach the magnitude reported in the present study and
probably underestimated the real burden of COPD. Also in
the present study, the prevalence of spirometric confirmed
COPD was much higher than the prevalence of physician
diagnosed COPD. Even the prevalence of at least GOLD
stage 2 COPD in subjects who smoked more than 20 pack
years (22%) was twice as high as the physician’s diagnosis of
COPD in the same group (11%). This problem of under-
diagnosis of COPD has been reported earlier.7,8 In the
“confronting COPD survey”1 COPD was underdiagnosed and
undertreated, in the Netherlands as well as in the six other
participating countries. In the Netherlands, 19% of patients
were undiagnosed despite having symptoms consistent with
COPD.
The prevalence of COPD increases with age and the
amount of smoked pack-years. A fixed ratio for FEV1/FVC to
classify COPD as proposed by GOLD5 may lead to increasing
false positive diagnosis of COPD with age, since FEV1/FVC
physiologically reduces with age.9 This misclassification
could be reduced by using the LLN for the FEV1/FVC ratio
and this could possibly better distinct physiology from
pathology. Using the LLN instead of the GOLD criterion to
define COPD in subjects older than 70 years in this study
population resulted in a reduction in COPD diagnosis from
42% to 27%. This was still substantially higher than in lower
age-categories. Obviously the cumulative effect of smokinghistory and inhalational exposures influence airflow limi-
tation in the elderly. Current and former smoking by
oneself are clearly related to age, with older men (age
60e69 years) having stunning ever-smoking prevalence up
to 85% This magnitude of ever-smoking has to mean that
environmental tobacco exposure has also been substantial
during the foregone decades before recognition of its
harmfulness.10
GOLD-defined COPD was found in 14% of persons who had
never smoked. According to the LLN this was still 6%.
Although never smokers were less likely to have COPD than
ever smokers, never smokers nonetheless comprised one
fifth of all subjects with COPD. Predictors of COPD in never
smokers in the international BOLD cohort included age,
education, occupational exposure, childhood respiratory
diseases and BMI alterations.11
As generally seen among the BOLD sites throughout the
world,12 also in the present study the overall prevalence of
COPD was higher in men than in women. It has been pre-
dicted that the expected changes in smoking behaviour will
result in a smaller increase of the projected prevalence in
men and greater increase in women.13 Given men and
women smoked equally in the present study, also in Maas-
tricht the gender difference in the prevalence of COPD will
equalise or possibly even reverse since women seem to
be more vulnerable to develop COPD.14 Already in the
young-est age group, the prevalence of COPD according to
the LLN tended to be higher in women than in men. This is
consistent with the remarkably high incidence of COPD in
the youngest women in the Rotterdam study.15
874 L.E.G.W. Vanfleteren et al.This study also has limitations. An important limitation is
the lower than desirable response rate which causes
uncertainty about the representativeness of the results. On
the other hand we nearly reached the sample size of at
least 300 men and 300 women as requested by the BOLD
protocol. The prevalence of non-responders was higher in
older age, but the sample individuals were weighted for the
whole population of Maastricht. Unacceptable spirometry
was more frequent in smokers. Another limitation was that
other potential causes of airflow limitation than COPD (e.g.
asthma, sarcoidosis, bronchiectasis, bronchiolar diseases)
were not excluded. However, BOLD methodology was
applied in the current survey, according to published
methods and protocol. According to BOLD standards, COPD
diagnosis was based on the lung function criteria without
requiring documented exposure to a known causative
agent.12
Although the Netherlands is a developed country and
COPD is a preventable disease, a surprisingly high burden
of COPD was found. With the ageing population and still
an important smoking prevalence, this burden is bound to
increase and impose great demands to public health care
and society. The government faces the important task to
continue the efforts to prevent the population from
exposure to noxious substances, most importantly
tobacco smoke. Health care professionals should give
priority to a better evaluation and diagnosis of patients
with COPD, as well as improved management of COPD and
take an aggressive attitude on the reduction of tobacco
smoking.
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